Low frequency of the V106M mutation among HIV-1 subtype C-infected pregnant women exposed to nevirapine.
Nevirapine used in single doses to prevent mother-to-child transmission has been shown to be associated with the development of transient resistant mutations. Here we describe the presence of V106M in seven out of 141 South African women (5%) 6 weeks after receiving nevirapine. V106M is a novel resistance mutation found in subtype C viruses exposed to efavirenz. This mutation is thus also induced at a low frequency in subtype C viruses exposed to single dose nevirapine.
Morris
Lynn
L
AIDS Virus Research Unit, National Institute for Communicable Diseases, Sandringham, Johannesburg, South Africa.
Pillay
Candice
C
Chezzi
Claudia
C
Lupondwana
Pumla
P
Ntsala
Matshediso
M
Levin
Leon
L
Venter
Francois
F
Martinson
Neil
N
Gray
Glenda
G
McIntyre
James
J
D000328:Adult; D003906:Developing Countries; D024882:Drug Resistance, Viral / Q000235:genetics*; D005260:Female; D005787:Gene Frequency; D015658:HIV Infections / Q000188:drug therapy / Q000821:virology*; D015497:HIV-1 / Q000145:classification / Q000235:genetics*; D006801:Humans; D007231:Infant, Newborn; D018445:Infectious Disease Transmission, Vertical / Q000517:prevention & control; D019829:Nevirapine / Q000627:therapeutic use; D011247:Pregnancy; D011251:Pregnancy Complications, Infectious / Q000188:drug therapy / Q000821:virology*; D018894:Reverse Transcriptase Inhibitors / Q000627:therapeutic use; D013019:South Africa
D018894:Reverse Transcriptase Inhibitors; D019829:Nevirapine